Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic le...
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031
About this item
Full title
Author / Creator
Children’s Oncology Group , from the Children’s Oncology Group , Schultz, K R , Carroll, A , Heerema, N A , Bowman, W P , Aledo, A , Slayton, W B , Sather, H , Devidas, M , Zheng, H W , Davies, S M , Gaynon, P S , Trigg, M , Rutledge, R , Jorstad, D , Winick, N , Borowitz, M J , Hunger, S P , Carroll, W L and Camitta, B
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
We previously reported preliminary findings that post induction imatinib mesylate (340 mg/m
2
/day), in combination with intensive chemotherapy, resulted in outcomes similar to blood and marrow transplant (BMT) for pediatric patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). We now report 5-year outcomes...
Alternative Titles
Full title
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4282929
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4282929
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/leu.2014.30
